GB2388026B - Use of epa and dha in secondary prevention of neurological events,particulary strokes - Google Patents

Use of epa and dha in secondary prevention of neurological events,particulary strokes

Info

Publication number
GB2388026B
GB2388026B GB0307625A GB0307625A GB2388026B GB 2388026 B GB2388026 B GB 2388026B GB 0307625 A GB0307625 A GB 0307625A GB 0307625 A GB0307625 A GB 0307625A GB 2388026 B GB2388026 B GB 2388026B
Authority
GB
United Kingdom
Prior art keywords
dha
epa
particulary
strokes
secondary prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0307625A
Other versions
GB0307625D0 (en
GB2388026A (en
Inventor
Philip Calder
Robert Grimble
Patrick Gallagher
Cliff Shearman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronova Biopharma Norge AS
Original Assignee
Pronova Biocare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biocare AS filed Critical Pronova Biocare AS
Priority to JP2004500857A priority Critical patent/JP4688203B2/en
Priority to CN03815692XA priority patent/CN1665496B/en
Priority to DE60329588T priority patent/DE60329588D1/en
Priority to ES03722833T priority patent/ES2334656T3/en
Priority to AU2003229993A priority patent/AU2003229993B2/en
Priority to AT03722833T priority patent/ATE444745T1/en
Priority to BR0309740-4A priority patent/BR0309740A/en
Priority to NZ548508A priority patent/NZ548508A/en
Priority to NZ536507A priority patent/NZ536507A/en
Priority to EP03722833A priority patent/EP1501493B1/en
Priority to CA2485116A priority patent/CA2485116C/en
Priority to PCT/GB2003/001945 priority patent/WO2003092673A1/en
Publication of GB0307625D0 publication Critical patent/GB0307625D0/en
Publication of GB2388026A publication Critical patent/GB2388026A/en
Priority to IL16498404A priority patent/IL164984A0/en
Priority to US10/979,751 priority patent/US8729124B2/en
Priority to NO20045275A priority patent/NO334959B1/en
Application granted granted Critical
Publication of GB2388026B publication Critical patent/GB2388026B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

<WC 1><WC 1><WC 1><WC 1><WC 1>Use of the n-3 polyunsaturated fatty acids EPA and /or DHA in the preparation of an oral medicament for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain.
GB0307625A 2002-03-05 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes Expired - Fee Related GB2388026B (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PCT/GB2003/001945 WO2003092673A1 (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention
CA2485116A CA2485116C (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention
EP03722833A EP1501493B1 (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention of strokes
CN03815692XA CN1665496B (en) 2002-05-03 2003-05-02 Use of EPA and DHA in Preparation of medicinie for secondary prevention of neurogenic diseases
AT03722833T ATE444745T1 (en) 2002-05-03 2003-05-02 USE OF EPA AND DHA FOR SECONDARY PREVENTION OF STROKE
BR0309740-4A BR0309740A (en) 2002-05-03 2003-05-02 Use of eicosapentaenoic acid (epa), docosaexaenoic acid (dha) or a mixture of epa and dha or a pharmaceutically acceptable salt or derivative thereof
NZ548508A NZ548508A (en) 2002-05-03 2003-05-02 Use of EPA and DHA in preventing cerebral damage wherein the dosage ranges from 0.5 to 5.0g of EPA and/or DHA daily
NZ536507A NZ536507A (en) 2002-05-03 2003-05-02 Use of eicosapentaenoic acid or docosahexaenoic acid or fish oil for prevention of cerebral damage in patients having symptoms of atherosclerosis or arteries supplying the brain i.e stroke
JP2004500857A JP4688203B2 (en) 2002-05-03 2003-05-02 Drugs using eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in secondary brain disease events such as stroke
DE60329588T DE60329588D1 (en) 2002-05-03 2003-05-02 USE OF EPA AND DHA FOR SECONDARY PREVENTION OF STROKE
AU2003229993A AU2003229993B2 (en) 2002-05-03 2003-05-02 Use of EPA and DHA in secondary prevention
ES03722833T ES2334656T3 (en) 2002-05-03 2003-05-02 USE OF EPA AND DHA IN SECONDARY PREVENTION OF BRAIN SPILLS.
IL16498404A IL164984A0 (en) 2002-05-03 2004-11-02 Use of epa and dha in secondary prevention
US10/979,751 US8729124B2 (en) 2002-03-05 2004-11-02 Use of EPA and DHA in secondary prevention
NO20045275A NO334959B1 (en) 2002-05-03 2004-12-01 Use of EPA and DHA in secondary prevention

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0210212.7A GB0210212D0 (en) 2002-05-03 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability

Publications (3)

Publication Number Publication Date
GB0307625D0 GB0307625D0 (en) 2003-05-07
GB2388026A GB2388026A (en) 2003-11-05
GB2388026B true GB2388026B (en) 2006-02-08

Family

ID=9936057

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0210212.7A Ceased GB0210212D0 (en) 2002-03-05 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0307625A Expired - Fee Related GB2388026B (en) 2002-03-05 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0210212.7A Ceased GB0210212D0 (en) 2002-03-05 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability

Country Status (6)

Country Link
JP (1) JP4688203B2 (en)
AT (1) ATE444745T1 (en)
DE (1) DE60329588D1 (en)
ES (1) ES2334656T3 (en)
GB (2) GB0210212D0 (en)
NZ (1) NZ536507A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160989A2 (en) 2013-03-28 2014-10-02 The Trustees Of Columbia University In The City Of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
WO2007059431A1 (en) * 2005-11-14 2007-05-24 The Trustees Of Columbia University In The City Of New York Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
CA2571462C (en) * 2006-02-07 2013-08-13 Mochida Pharmaceutical Co., Ltd. Composition for preventing recurrence of stroke
AU2007271900B2 (en) * 2006-07-14 2013-05-23 Nattopharma As Pharmaceutical and nutraceutical products comprising vitamin K2
AU2009315314B2 (en) 2008-11-14 2013-04-18 Bomi P. Framroze A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
JP6176894B2 (en) 2009-03-09 2017-08-09 プロノヴァ・バイオファーマ・ノルゲ・アーエス Composition comprising fatty acid oil mixture and surfactant, and method and use thereof
KR101904388B1 (en) * 2009-10-23 2018-10-05 프로노바 바이오파마 너지 에이에스 Coated capsules and tablets of a fatty acid oil mixture
DE202017007311U1 (en) * 2016-06-30 2020-10-09 Rudolf Krumbholz Application and preparation for maintaining and improving cognitive functions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
WO2000044361A2 (en) * 1999-01-27 2000-08-03 Laxdale Limited Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2534557B2 (en) * 1989-03-30 1996-09-18 全国農業協同組合連合会 Method for producing feed for pork and pork for meat
JPH05271685A (en) * 1991-12-26 1993-10-19 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai Oil or fat composition containing highly unsaturated fatty acid and production of glyceride oil containing highly unsaturated fatty acid
IT1264987B1 (en) * 1993-12-14 1996-10-17 Prospa Bv SALTS OF A POLYUNSATURATED FATTY ACID AND PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM
IT1274734B (en) * 1994-08-25 1997-07-24 Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
JPH1180083A (en) * 1997-09-10 1999-03-23 Nof Corp Production of eicosapentaenoic ester
JP2000159678A (en) * 1998-11-30 2000-06-13 Nof Corp Ointment preparation
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
JP2001131088A (en) * 1999-11-02 2001-05-15 Kyurin:Kk Therapeutic agent for syndrome x
HU229375B1 (en) * 2000-05-05 2013-11-28 Inst Nat Sante Rech Med Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
WO2000044361A2 (en) * 1999-01-27 2000-08-03 Laxdale Limited Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders

Also Published As

Publication number Publication date
GB0210212D0 (en) 2002-06-12
GB0307625D0 (en) 2003-05-07
DE60329588D1 (en) 2009-11-19
ATE444745T1 (en) 2009-10-15
NZ536507A (en) 2008-12-24
GB2388026A (en) 2003-11-05
JP2005529903A (en) 2005-10-06
JP4688203B2 (en) 2011-05-25
ES2334656T3 (en) 2010-03-15

Similar Documents

Publication Publication Date Title
HK1058883A1 (en) Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin&#39;s lymphoma and psychiatric or neurological disorders.
IL129367A0 (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
PT1310249E (en) UTILIZATION OF POLY-INSATURATED FATTY ACIDS FOR PRIMARY PREVENTION OF SERIOUS CARDIOVASCULAR EVENTS
YU59303A (en) Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
AU2003210210A1 (en) The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
BR0309740A (en) Use of eicosapentaenoic acid (epa), docosaexaenoic acid (dha) or a mixture of epa and dha or a pharmaceutically acceptable salt or derivative thereof
AU2003208920A1 (en) Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
MXPA02012689A (en) Therapeutic combinations of fatty acids.
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
NZ299464A (en) Use of gamma linolenic or dihomogamma linolenic acid in the treatment of Huntington&#39;s Chorea
PT1152755E (en) ESSENTIAL FATTY ACIDS INTENDED FOR THE PREVENTION OF CARDIOVASCULAR ACCIDENTS
SE0303513D0 (en) Use of a fatty acid composition comprising at least one of epa and any or any combination thereof
FR2860976B1 (en) NOVEL SYNERGISTIC COMPOSITIONS FOR IMPROVING THE BIODAVAILABILITY AND EFFICIENCY OF POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF BRAIN FUNCTIONING DISORDERS.
AU2003217759A1 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
HK1052298A1 (en) High lipid diet
GB2388026B (en) Use of epa and dha in secondary prevention of neurological events,particulary strokes
SG149825A1 (en) Body taste improver comprising long-chain highly unsaturated fatty acid and/or ester thereof
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
MY131357A (en) Fatty acid treatment
WO2005053669A8 (en) Use of omega-3 polyunsaturated fatty acids for sleep apnoea
NZ525536A (en) Treatment of arthritis and other similar conditions
AU2001285026A1 (en) Methods and compositions for use in the diagnosis and treatment of chronic immune disease
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20150402